HRP20161575T1 - Sulfatirane hijaluronske kiseline kao sredstva za reguliranje aktivnosti citokina - Google Patents
Sulfatirane hijaluronske kiseline kao sredstva za reguliranje aktivnosti citokina Download PDFInfo
- Publication number
- HRP20161575T1 HRP20161575T1 HRP20161575TT HRP20161575T HRP20161575T1 HR P20161575 T1 HRP20161575 T1 HR P20161575T1 HR P20161575T T HRP20161575T T HR P20161575TT HR P20161575 T HRP20161575 T HR P20161575T HR P20161575 T1 HRP20161575 T1 HR P20161575T1
- Authority
- HR
- Croatia
- Prior art keywords
- hyaluronic acid
- sulfated hyaluronic
- hyaluronic acids
- cytokine activity
- sulphated hyaluronic
- Prior art date
Links
- 229920002674 hyaluronan Polymers 0.000 title claims 3
- 102000004127 Cytokines Human genes 0.000 title 1
- 108090000695 Cytokines Proteins 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 title 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical class CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 8
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 229960003160 hyaluronic acid Drugs 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000019635 sulfation Effects 0.000 claims 2
- 238000005670 sulfation reaction Methods 0.000 claims 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 108010002586 Interleukin-7 Proteins 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Emergency Medicine (AREA)
- AIDS & HIV (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Biotechnology (AREA)
- Obesity (AREA)
Claims (4)
1. Sulfatirana hialuronska kiselina za upotrebu u sprječavanju i/ili liječenju astme povezane s aktiviranjem IL-1, IL-2, IL-6, IL-7, IL-8, IL-12 te TNF, s time da rečena sulfatirana hialuronska kiselina (HA) ima molekulsku masu u rasponu od 10,000 do 50,000 Da, 150,000 do 250,000 Da te 500,000 do 750,000 Da te da stupanj sulfatiranja jest 1 ili do 3.
2. Sulfatirana hialuronska kiselina za upotrebu u sprječavanju i/ili liječenju imunodeficijentnog ekcema i dermatitisa povezanih s manjkom IL-10, s time da rečena sulfatirana hialuronska kiselina (HA) ima molekulsku masu u rasponu od 10,000 do 50,000 Da, 150,000 do 250,000 Da te 500,000 do 750,000 Da te da stupanj sulfatiranja jest 1 ili do 3.
3. Sulfatirana hialuronska kiselina za upotrebu prema prethodnim patentnim zahtjevima za sistemsko davanje.
4. Sulfatirana hialuronska kiselina prema patentnim zahtjevima 1-3 za topikalno davanje ili davanje inhalacijom.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITPD2009A000135A IT1397247B1 (it) | 2009-05-14 | 2009-05-14 | Nuovi agenti regolatori dell'attivita' citochinica |
EP10721125.2A EP2429533B1 (en) | 2009-05-14 | 2010-05-11 | Sulphated hyaluronic acids as regulator agents of the cytokine activity |
PCT/EP2010/003044 WO2010130466A1 (en) | 2009-05-14 | 2010-05-11 | Sulphated hyaluronic acids as regulator agents of the cytokine activity |
Publications (2)
Publication Number | Publication Date |
---|---|
HRP20161575T1 true HRP20161575T1 (hr) | 2016-12-30 |
HRP20161575T8 HRP20161575T8 (hr) | 2019-01-25 |
Family
ID=41268269
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20161575TT HRP20161575T8 (hr) | 2009-05-14 | 2016-11-25 | Sulfatirane hijaluronske kiseline kao sredstva za reguliranje aktivnosti citokina |
Country Status (16)
Country | Link |
---|---|
US (2) | US9808482B2 (hr) |
EP (2) | EP3103459B1 (hr) |
CN (2) | CN108379288B (hr) |
CA (2) | CA2761627C (hr) |
ES (2) | ES2602498T3 (hr) |
HK (1) | HK1258973A1 (hr) |
HR (1) | HRP20161575T8 (hr) |
HU (1) | HUE031174T2 (hr) |
IT (1) | IT1397247B1 (hr) |
LT (1) | LT2429533T (hr) |
PL (1) | PL2429533T3 (hr) |
PT (1) | PT2429533T (hr) |
RU (1) | RU2552337C2 (hr) |
SI (1) | SI2429533T1 (hr) |
SM (1) | SMT201600456B (hr) |
WO (1) | WO2010130466A1 (hr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8343942B2 (en) * | 2008-04-04 | 2013-01-01 | University Of Utah Research Foundation | Methods for treating interstitial cystitis |
KR101594552B1 (ko) | 2008-04-04 | 2016-02-17 | 유니버시티 오브 유타 리서치 파운데이션 | 알킬화된 반합성 글리코사미노글리코산 에테르 및 이의 제조 및 사용 방법 |
IT1397246B1 (it) * | 2009-05-14 | 2013-01-04 | Fidia Farmaceutici | Nuovi medicamenti ad uso topico a base di acido ialuronico solfatato come agente attivante o inibente l'attivita' citochinica |
US20130209531A1 (en) | 2010-06-08 | 2013-08-15 | University Of Utah Research Foundation | Applications of partially and fully sulfated hyaluronan |
CA2830933A1 (en) | 2011-03-23 | 2012-09-27 | University Of Utah Research Foundation | Methods for treating or preventing urological inflammation |
GB201219696D0 (en) * | 2012-11-01 | 2012-12-12 | Univ Liverpool | Agents for the prevention and/or treatment of central nervous system damamge |
US11337994B2 (en) | 2016-09-15 | 2022-05-24 | University Of Utah Research Foundation | In situ gelling compositions for the treatment or prevention of inflammation and tissue damage |
CN109529021B (zh) * | 2019-01-25 | 2022-11-15 | 山东省分析测试中心 | 一种白细胞介素2抑制破骨细胞生成和功能的新用途 |
IT201900003887A1 (it) | 2019-03-18 | 2020-09-18 | Fidia Farm Spa | Sistemi di stabilizzazione e di rilascio controllato di farmaci instabili alla sterilizzazione |
WO2021133000A1 (ko) * | 2019-12-23 | 2021-07-01 | 주식회사 엘지화학 | 항염 또는 항혈관신생용 약제학적 조성물 |
WO2021179047A1 (en) | 2020-03-12 | 2021-09-16 | Cullis Hill Sydney David | Treatment for coronavirus infection and associated cytokine toxicity |
IT202000032243A1 (it) * | 2020-12-23 | 2022-06-23 | Fidia Farm Spa | Nuovi agenti antivirali |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0240098A3 (en) * | 1986-04-04 | 1989-05-10 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Oligo and polysaccharides for the treatment of diseases caused by retroviruses |
IT1217458B (it) * | 1988-05-02 | 1990-03-22 | Crinos Ind Farmacoriologica S | Sulfoamino derivati di condroitin solfati,del dermatan solfato e dell' acido ialuronico e loro proprieta' farmacologiche |
CA1340994C (en) * | 1989-09-21 | 2000-05-16 | Rudolf Edgar Dr. Falk | Treatment of conditions and disease |
DE4021066A1 (de) * | 1990-07-03 | 1992-01-09 | Hoechst Ag | Langzeitprophylaxe gegen erkrankungen, die durch viren oder durch unkonventionelle viren verursacht werden |
ITPD940054A1 (it) | 1994-03-23 | 1995-09-23 | Fidia Advanced Biopolymers Srl | Polisaccaridi solfatati |
US5872109A (en) * | 1995-02-07 | 1999-02-16 | Shiseido Company, Ltd. | Anti-inflammatory agent |
JPH10195107A (ja) * | 1997-01-10 | 1998-07-28 | Shiseido Co Ltd | オリゴ硫酸化ヒアルロン酸 |
AU738788B2 (en) | 1997-04-04 | 2001-09-27 | Fidia Farmaceutici S.P.A. | N-sulphated hyaluronic acid compounds, derivatives thereof and a process for their preparation |
US5981509A (en) * | 1997-05-20 | 1999-11-09 | Shiseido Company, Ltd. | Preparation for prophylaxis or treatment of renal diseases containing sulfated polysaccharide |
JPH11147901A (ja) * | 1997-11-19 | 1999-06-02 | Maruho Co Ltd | カリクレイン−キニン系阻害剤 |
JPH11269077A (ja) | 1998-03-19 | 1999-10-05 | Maruho Co Ltd | ホスホリパーゼa2阻害用医薬組成物 |
DE19813234A1 (de) * | 1998-03-26 | 1999-09-30 | Knoell Hans Forschung Ev | Verfahren zur Herstellung hochsulfatierter Hyaluronsäuren |
JP2000178196A (ja) | 1998-12-11 | 2000-06-27 | Seikagaku Kogyo Co Ltd | 新規ヒアルロニダーゼ阻害剤及び外用剤 |
JP2001163789A (ja) * | 1999-12-13 | 2001-06-19 | Maruho Co Ltd | マトリックスメタロプロテアーゼ阻害用医薬組成物 |
GB0003048D0 (en) * | 2000-02-11 | 2000-03-29 | Dealler Stephen F | The therapeutic use of polysulphonated polyglycosides or other polyanionic compounds in autism |
US7431920B2 (en) * | 2000-07-19 | 2008-10-07 | Pepgen Corporation | Method of treating IL-10 deficiency |
DE10053053A1 (de) * | 2000-10-19 | 2002-05-16 | Knoell Hans Forschung Ev | Pharmazeutische Formulierungen zur Hemmung von entzündlichen Arthritiden |
US20030162732A1 (en) * | 2001-07-05 | 2003-08-28 | Astion Development A/S | Combination of aminosugars and cysteine or cysteine derivatives |
ITPD20020271A1 (it) * | 2002-10-18 | 2004-04-19 | Fidia Farmaceutici | Composti chimico-farmaceutici costituiti da derivati dei taxani legati covalentemente all'acido ialuronico o ai suoi derivati. |
DE10349722A1 (de) * | 2003-10-23 | 2005-06-16 | Beschorner, Katharina, Dr. | Zusammensetzung zur Arthrose-/Arthritisbehandlung, insbesondere von Gelenken |
DE10352137A1 (de) * | 2003-11-04 | 2005-06-16 | Beschorner, Katharina, Dr. | Verwendung sulfatierter Hyaluronsäure |
ITPD20040245A1 (it) * | 2004-10-08 | 2005-01-08 | Fidia Advanced Biopolymers Srl | Biomateriali costituiti da acido ialuronico solfatato e gellano utilizzabili nella prevenzione delle adesioni spinali |
DE102005004643B4 (de) * | 2005-01-28 | 2010-04-08 | Innovent E.V. Technologieentwicklung | Antivirale Kombinationen sowie ihre Verwendung |
ITPD20050168A1 (it) * | 2005-06-01 | 2006-12-02 | Fidia Advanced Biopolymers Srl | Formulazioni di acido lipoico ed acido ialuronico e o suoi derivati e loro impiego in campo farmaceutico e cosmetico |
US7517856B2 (en) * | 2005-10-11 | 2009-04-14 | Ben-Gurion University Of The Negev Research And Development Authority | Bioconjugates comprising sulfated polysaccharides and their uses |
JP4220513B2 (ja) * | 2005-12-01 | 2009-02-04 | 株式会社資生堂 | カチオン化ヒアルロン酸 |
ITPD20060219A1 (it) * | 2006-05-31 | 2007-12-01 | Fidia Farmaceutici | Composizioni farmaceutiche contenenti acido ialuronico solfatato nel trattamento dell'osteoartrosi |
EP2025687A1 (en) * | 2007-07-23 | 2009-02-18 | Istituto Scientifico di Chimica E Biochimica "G Ronzoni | Process for the preparation of heparanase-inhibiting sulfated hyaluronates and products obtained thereby |
EP2090308A1 (en) * | 2008-02-15 | 2009-08-19 | Bone Therapeutics | Pharmaceutical composition for the treatment or prevention of osteoarticular diseases |
IT1397246B1 (it) * | 2009-05-14 | 2013-01-04 | Fidia Farmaceutici | Nuovi medicamenti ad uso topico a base di acido ialuronico solfatato come agente attivante o inibente l'attivita' citochinica |
-
2009
- 2009-05-14 IT ITPD2009A000135A patent/IT1397247B1/it active
-
2010
- 2010-05-11 LT LTEP10721125.2T patent/LT2429533T/lt unknown
- 2010-05-11 PL PL10721125T patent/PL2429533T3/pl unknown
- 2010-05-11 EP EP16178622.3A patent/EP3103459B1/en active Active
- 2010-05-11 CA CA2761627A patent/CA2761627C/en active Active
- 2010-05-11 ES ES10721125.2T patent/ES2602498T3/es active Active
- 2010-05-11 ES ES16178622T patent/ES2722436T3/es active Active
- 2010-05-11 WO PCT/EP2010/003044 patent/WO2010130466A1/en active Application Filing
- 2010-05-11 HU HUE10721125A patent/HUE031174T2/en unknown
- 2010-05-11 CA CA2967567A patent/CA2967567C/en active Active
- 2010-05-11 CN CN201810521049.XA patent/CN108379288B/zh active Active
- 2010-05-11 EP EP10721125.2A patent/EP2429533B1/en active Active
- 2010-05-11 SI SI201031341A patent/SI2429533T1/sl unknown
- 2010-05-11 PT PT107211252T patent/PT2429533T/pt unknown
- 2010-05-11 US US13/320,015 patent/US9808482B2/en active Active
- 2010-05-11 RU RU2011146049/15A patent/RU2552337C2/ru active IP Right Revival
- 2010-05-11 CN CN201080020643.2A patent/CN102421443B/zh active Active
-
2016
- 2016-11-25 HR HRP20161575TT patent/HRP20161575T8/hr unknown
- 2016-12-14 SM SM201600456T patent/SMT201600456B/it unknown
-
2017
- 2017-09-20 US US15/710,275 patent/US10548918B2/en active Active
-
2019
- 2019-01-28 HK HK19101455.5A patent/HK1258973A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
RU2011146049A (ru) | 2013-06-20 |
EP3103459B1 (en) | 2019-02-27 |
CA2761627C (en) | 2017-07-04 |
ITPD20090135A1 (it) | 2010-11-15 |
CN108379288A (zh) | 2018-08-10 |
IT1397247B1 (it) | 2013-01-04 |
HUE031174T2 (en) | 2017-06-28 |
PT2429533T (pt) | 2016-11-14 |
EP2429533B1 (en) | 2016-09-07 |
US10548918B2 (en) | 2020-02-04 |
SMT201600456B (it) | 2017-01-10 |
US20120101059A1 (en) | 2012-04-26 |
LT2429533T (lt) | 2016-12-12 |
US9808482B2 (en) | 2017-11-07 |
WO2010130466A1 (en) | 2010-11-18 |
SI2429533T1 (sl) | 2017-01-31 |
CA2761627A1 (en) | 2010-11-18 |
CN108379288B (zh) | 2020-10-16 |
CA2967567A1 (en) | 2010-11-18 |
CN102421443A (zh) | 2012-04-18 |
CA2967567C (en) | 2018-09-11 |
ES2602498T3 (es) | 2017-02-21 |
EP3103459A2 (en) | 2016-12-14 |
HK1258973A1 (zh) | 2019-11-22 |
ES2722436T3 (es) | 2019-08-12 |
PL2429533T3 (pl) | 2017-02-28 |
EP3103459A3 (en) | 2017-01-18 |
EP2429533A1 (en) | 2012-03-21 |
US20180008628A1 (en) | 2018-01-11 |
CN102421443B (zh) | 2018-06-26 |
HRP20161575T8 (hr) | 2019-01-25 |
RU2552337C2 (ru) | 2015-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20161575T1 (hr) | Sulfatirane hijaluronske kiseline kao sredstva za reguliranje aktivnosti citokina | |
HRP20161574T1 (hr) | Novi lijekovi za topikalnu primjenu temeljeni na sulfatiranoj hijaluronskoj kiselini kao sredstvu za aktiviranje ili inhibiciju aktivnosti citokina | |
CY1122189T1 (el) | Ιονικες υδατικες συνθεσεις | |
MY167691A (en) | A pharmaceutical spray composition comprising a vitamin d analogue and a corticosteroid | |
PE20150997A1 (es) | Nanoparticulas terapeuticas que comprenden un agente terapeutico y metodos para realizarlas y usarlas | |
CL2012001836A1 (es) | Compuestos de pirazol, antagonista de crth2; composicion farmacéutica; uso en el tratamiento de trastornos inflamatorios, infecciosos, inmunoreguladores, enfermedades respiratorias, gastrointestinales o dolencias, entre otros. | |
TN2017000270A1 (en) | Use of prg4 as an anti-inflammatory agent | |
MX2014007122A (es) | Nuevos glucosaminoglucanos con baja actividad anticoagulante. | |
TN2014000236A1 (en) | Use of chemically modified heparin derivates in sickle cell disease | |
BR112014032239A2 (pt) | inibidores da família de mir-15 de micro-rnas | |
CO6230979A2 (es) | Uso de quitosanas para incrementar el indice de crecimiento de las uñas | |
BR112015015864A8 (pt) | composição farmacêutica, e, uso de uma composição farmacêutica | |
WO2012022681A3 (en) | Heterocyclyl pyrazolopyrimidine analogues as selective jak inhibitors | |
AR065317A1 (es) | Uso de quitosanos, derivados de quitosanos y una sal fisiologicamente aceptable del mismo para el tratamiento de enfermedades inflamatorias ungueales | |
WO2006130426A3 (en) | Modulators of ccr-5 activity | |
BR112012029304A2 (pt) | copolíme-ros em bloco de polissiloxano e seu uso em formulações cosmeticas | |
JP2015514705A5 (hr) | ||
MX2012013607A (es) | Polisacarido de las semillas de tamarindo para usarse en el tatamiento de enfermedades inflamatorias. | |
JP2015511664A5 (hr) | ||
FR2977494B1 (fr) | Compositions cosmetiques ou pharmaceutiques contenant des acides hyaluroniques de masses moleculaires differentes | |
BR112013028285A2 (pt) | indução de il-12 usando imunoterapia | |
WO2014127232A3 (en) | Methods for maintaining population of therapeutic cells in treatment site of subject in need of cell therapy | |
EP2508190A4 (en) | MACROPHAGIC PHAGOCYTOSIS-ACTIVE COMPOSITION AND / OR COMPOSITION FOR PROMOTING CYTOKINE PRODUCTION IN MACROPHAGES | |
MA34933B1 (fr) | Preparation de nouveaux bio-composites chitosan-argile modifiee | |
AR082653A1 (es) | Composicion farmaceutica topica que comprende heparina |